Product Description
For Advanced Non-Hematologic Malignancies (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00820768)
Mechanisms of Action: HSP90 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00820768 |
CA501 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified |
2013-04-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|